nach oben

Nuclear Medicine and Molecular Imaging

Erschienen in:

18.12.2017 | Perspective

PERCIST in Perspective

verfasst von: Joo Hyun O, Richard L. Wahl

Erschienen in: Nuclear Medicine and Molecular Imaging | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Positron Emission tomography Response Criteria In Solid Tumors (PERCIST) version 1.0 was introduced in 2009 for objective assessment of tumor metabolic response using ¹⁸F-FDG PET/CT. Practical PERCIST: A Simplified Guide to PET Response Criteria in Solid Tumors 1.0 was published in 2016 to review and clarify some of the issues with the PERCIST. In this article, we reflect on the benefits and challenges of implementing PERCIST, and speculate on topics that could be discussed in PERCIST 1.1 in the future.

Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):122S–50S.CrossRefPubMedPubMedCentral

O JH, Lodge MA, Wahl RL. Practical PERCIST: a simplified guide to PET Response Criteria in Solid Tumors 1.0. Radiology. 2016;280(2):576-84.

Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of cancer (EORTC) PET study group. Eur J Cancer. 1999;35:1773–82.CrossRefPubMed

Jacene HA, Leboulleux S, Baba S, Chatzifotiadis D, Goudarzi B, Teytelbaum O, et al. Assessment of interobserver reproducibility in quantitative 18F-FDG PET and CT measurements of tumor response to therapy. J Nucl Med. 2009;50:1760–9.CrossRefPubMed

Tahari AK, Chien D, Azadi JR, Wahl RL. Optimum lean body formulation for correction of standardized uptake value in PET imaging. J Nucl Med. 2014;55:1481–4.CrossRefPubMedPubMedCentral

Leal J, Wahl R. Auto-PERCIST™: Semi-automated quantitative assessment of FDG-PET based on the PERCIST criteria. Radiological Society of North America 2013 Scientific Assembly and Annual Meeting, Chicago, 2013.

Pinker K, Riedl CC, Ong L, Jochelson M, Ulaner GA, McArthur H, et al. The impact that number of analyzed metastatic breast cancer lesions has on response assessment by 18F-FDG PET/CT using PERCIST. J Nucl Med. 2016;57:1102–4.CrossRefPubMedPubMedCentral

Oo JH, Jacene H, Stearns V, Wahl R. How many lesions to measure for response assessment? Comparing SULpeak changes in a single lesion and the sum of the 5 hottest lesions in 3 types of cancer and 3 types of therapy. J Nucl Med. 2013;54:229.CrossRef

Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059–68.CrossRefPubMedPubMedCentral

10.

Suzuki H, Nishio M, Nakanishi H, Hanai N, Hirakawa H, Kodaira T, et al. Impact of total lesion glycolysis measured by 18F-FDG-PET/CT on overall survival and distant metastasis in hypopharyngeal cancer. Oncol Lett. 2016;12:1493–500.CrossRefPubMedPubMedCentral

11.

Ho KC, Fang YD, Chung HW, Liu YC, Chang JW, Hou MM, et al. TLG-S criteria are superior to both EORTC and PERCIST for predicting outcomes in patients with metastatic lung adenocarcinoma treated with erlotinib. Eur J Nucl Med Mol Imaging. 2016;43(12):2155-2165.

12.

Lee JW, Heo EJ, Moon SH, Lee H, Cheon GJ, Lee M, et al. Prognostic value of total lesion glycolysis on preoperative 18F-FDG PET/CT in patients with uterine carcinosarcoma. Eur Radiol. 2016;26(11):4148-4154

13.

Kim HS, Choi JY, Choi DW, Lim HY, Lee JH, Hong SP, et al. Prognostic value of volume-based metabolic parameters measured by (18)F-FDG PET/CT of pancreatic neuroendocrine tumors. Nucl Med Mol Imaging. 2014;48:180–6.CrossRefPubMedPubMedCentral

14.

Rahmim A, Schmidtlein C, Bak-Fredslund K, Subramaniam R, Morsing A, Keiding S, et al. Application of novel PET metric to quantify liver metastases for enhanced prognostication of clinical outcome. J Nucl Med. 2016;57:352.

15.

Kang SR, Song HC, Byun BH, Oh JR, Kim HS, Hong SP, et al. Intratumoral metabolic heterogeneity for prediction of disease progression after concurrent Chemoradiotherapy in patients with inoperable stage III non-small-cell lung cancer. Nucl Med Mol Imaging. 2014;48:16–25.CrossRefPubMed

16.

Kim DH, Jung JH, Son SH, Kim CY, Hong CM, Oh JR, et al. Prognostic significance of Intratumoral metabolic heterogeneity on 18F-FDG PET/CT in pathological N0 non-small cell lung cancer. Clin Nucl Med. 2015;40:708–14.CrossRefPubMed

17.

Riedl CC, Pinker K, Ulaner GA, Ong LT, Baltzer P, Jochelson MS, et al. Comparison of FDG-PET/CT and contrast-enhanced CT for monitoring therapy response in patients with metastatic breast cancer. Eur J Nucl Med Mol Imaging. 2017;44:1428–37.CrossRefPubMed

18.

Shang J, Ling X, Zhang L, Tang Y, Xiao Z, Cheng Y, et al. Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2016;43:1945–53.CrossRefPubMed

19.

Yanagawa M, Tatsumi M, Miyata H, Morii E, Tomiyama N, Watabe T, et al. Evaluation of response to neoadjuvant chemotherapy for esophageal cancer: PET response criteria in solid tumors versus response evaluation criteria in solid tumors. J Nucl Med. 2012;53:872–80.CrossRefPubMed

20.

Ding Q, Cheng X, Yang L, Zhang Q, Chen J, Li T, et al. PET/CT evaluation of response to chemotherapy in non-small cell lung cancer: PET response criteria in solid tumors (PERCIST) versus response evaluation criteria in solid tumors (RECIST). J Thorac Dis. 2014;6:677–83.PubMedPubMedCentral

21.

Koshkin VS, Bolejack V, Schwartz LH, Wahl RL, Chugh R, Reinke DK, et al. Assessment of imaging modalities and response metrics in Ewing sarcoma: correlation with survival. J Clin Oncol 2016;34(30):3680–3685.

Titel: PERCIST in Perspective
verfasst von: Joo Hyun O
Richard L. Wahl
Publikationsdatum: 18.12.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: Nuclear Medicine and Molecular Imaging / Ausgabe 1/2018
Print ISSN: 1869-3474
Elektronische ISSN: 1869-3482
DOI: https://doi.org/10.1007/s13139-017-0507-4

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

PERCIST in Perspective

Abstract

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2018

Development of tau PET Imaging Ligands and their Utility in Preclinical and Clinical Studies

Injection of Botulinum Toxin for Preventing Salivary Gland Toxicity after PSMA Radioligand Therapy: an Empirical Proof of a Promising Concept

Obesity and Brain Positron Emission Tomography

Transiently Altered Distribution of F-18 FDG in a Patient with Subacute Thyroiditis

Current Methods to Define Metabolic Tumor Volume in Positron Emission Tomography: Which One is Better?

Multiple Regression Analysis of Predictors of Bone Scintigraphy Positivity in Patients with Head and Neck Cancers